An extract from the Investor presentation dated 21/02/2024:
"Programmed death ligand 1 (PD-L1) expression is an FDA-approved predictive biomarker of the success of PD-1/PD-L1 inhibitor therapy for patients with non-small cell lung cancer. The method used to assess the level of PD-L1 in NSCLC is three different expression levels: high (TPS >50%), low (TPS 1-49%), and negative (TPS <1%) [...]. Generally speaking, the way NSCLC patients are expected to respond to anti-PD-(L)1 therapies is grouped by these three levels of PD-L1 expression: high expressors respond best, low expressors respond sub-optimally, and negative expressors are not expected to respond at all or have negligible responses [...]. For negative expressing patients (TPS <1%), none of these chemo-free IO therapies are approved."
- Forums
- ASX - By Stock
- IMM
- Ann: Positive preliminary topline results from TACTI-003 Cohort B
Ann: Positive preliminary topline results from TACTI-003 Cohort B, page-9
-
- There are more pages in this discussion • 43 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
|
|||||
Last
39.0¢ |
Change
-0.010(2.50%) |
Mkt cap ! $562.8M |
Open | High | Low | Value | Volume |
39.0¢ | 39.5¢ | 38.5¢ | $997.5K | 2.559M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 85852 | 38.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
39.0¢ | 75389 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 85852 | 0.385 |
9 | 274350 | 0.380 |
3 | 35464 | 0.375 |
5 | 94020 | 0.370 |
2 | 11078 | 0.365 |
Price($) | Vol. | No. |
---|---|---|
0.390 | 75389 | 4 |
0.395 | 44264 | 2 |
0.400 | 176281 | 6 |
0.405 | 187434 | 3 |
0.410 | 296117 | 10 |
Last trade - 16.10pm 04/09/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |